GAD2 and type 1 diabetes mellitus: A comparative study, feeding either recombinant vIL-10 or the recombinant endogenous mIL-10 together with the GAD65 auto-antigen to NOD mice, would therefore allow to evaluate and assess the outcome of the different immunomodulatory properties of the viral cytokine in inducing oral tolerance in the animal model, and to evaluate the possibility of exploiting vIL-10 for the prevention of T1DM.